UPDATE: Jefferies & Company Reiterates Hold Rating, Lowers PT on Aveo Pharmaceuticals
In a report published Wednesday, Jefferies & Company reiterated its Hold rating on Aveo Pharmaceuticals (NASDAQ: AVEO), but lowered its price target from $11.00 to $9.00.
Jefferies noted, “Aveo announced a strategic restructuring, which will extend its current cash to year-end 2013. This is an incremental positive, although it does not eliminate the company's near-term search for additional capital. The primary focus for investors remains the regulatory prospects for tivozanib in renal cell carcinoma.”
Aveo Pharmaceuticals closed on Tuesday at $7.87.
Latest Ratings for AVEO
|May 2016||PiperJaffray||Initiates Coverage on||Overweight|
|Mar 2016||FBR Capital||Initiates Coverage on||Outperform|
|Mar 2015||RBC Capital||Upgrades||Underperform||Sector Perform|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.